NVG-cardio, LLC

The Institute of Human Stem Cells (Moscow) subsidiary company, registered in May 2015 to carry out research, development and implementation of the intellectual activity results in the field of creating innovative gene therapy products for the treatment of cardiovascular disease, the most common cause of death in the Russian Federation. The implementation of the tasks is planned in cooperation with the Meshalkin National Medical Research Centre of the Russian Ministry of Health.